Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


27.03.2017

1 Am J Dermatopathol
1 Ann Surg Oncol
2 Anticancer Res
2 Br J Cancer
3 Br J Dermatol
1 Cancer
1 J Am Acad Dermatol
1 J Surg Oncol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. RIVEIRO-FALKENBACH E, Santos-Briz A, Rios-Martin JJ, Rodriguez-Peralto JL, et al
    Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.
    Am J Dermatopathol. 2017;39:291-295.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. MORTON RL, Tran A, Vessey JY, Rowbotham N, et al
    Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications.
    Ann Surg Oncol. 2017 Mar 20. doi: 10.1245/s10434-017-5842.
    PubMed     Text format     Abstract available


    Anticancer Res


  3. Melanoma Development. Molecular Biology, Genetics and Clinical Application.
    Anticancer Res. 2017;37:1544.
    PubMed     Text format    

  4. YOSHIKAWA S, Kiyohara Y, Otsuka M, Kondou R, et al
    Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Anticancer Res. 2017;37:1321-1328.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    

  6. IMAFUKU K, Yoshino K, Yamaguchi K, Tsuboi S, et al
    Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    Br J Dermatol

  7. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed     Text format    

  8. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Text format     Abstract available

  9. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed     Text format    


    Cancer

  10. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  11. SCHER RK, Lipner SR
    Pediatric melanomas often mimic benign skin lesions.
    J Am Acad Dermatol. 2017;76:e131.
    PubMed     Text format    


    J Surg Oncol

  12. LORIMER PD, Benham EC, Walsh K, Han Y, et al
    Reporting of mitotic rate in cutaneous melanoma: A study using the national cancer data base.
    J Surg Oncol. 2017;115:281-286.
    PubMed     Text format     Abstract available


    PLoS One

  13. LUO L, Orlow I, Kanetsky PA, Thomas NE, et al
    No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival.
    PLoS One. 2017;12:e0174234.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: